DG Comp punishes Lundbeck over pay-for-delay
Wednesday, 19 June 2013 (over a year ago)
The European Commission has fined pharmaceutical company Lundbeck €94 million and several generic drug makers €52 million for delaying the entry of generic drugs to the EU market. It is the first fine issued in a reverse-payment case under European law.
Premium Subscription required to view this article
This content can only be accessed by Premium subscribers.
This content is part of the GCR archive and can only be accessed by subscribers with a Premium Subscription.
If you are a subscriber, please login: